Cytokinetics Inc (CYTK): Mark Lampert’s Biotechnology Value Fund Loads Up On More Shares

Page 1 of 14

Mark Lampert‘s Biotechnology Value Fund has filed a Form 13G on Cytokinetics, Inc. (NASDAQ:CYTK), one of its top-10 holdings at the end of 2015. The filing reveals an increase of nearly 1.00 million shares to the fund’s holding since then, lifting it to 3.91 million shares and ownership of just over 10% of the company’s stock. The full content of the filing can be found below.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Trading Fund OS 0 342,985 0 342,985 342,985 Less than 1%
BVF Partners OS Ltd 0 342,985 0 342,985 342,985 Less than 1%
BVF Partners 0 3,908,329 0 3,908,329 3,908,329 10.1%
BVF Inc 0 3,908,329 0 3,908,329 3,908,329 10.1%
Mark N. Lampert 0 3,908,329 0 3,908,329 3,908,329 10.1%

Follow Mark Lampert's Biotechnology Value Fund / BVF Inc

Page 1 of 14 SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 3)1
Cytokinetics, Incorporated
 (Name of Issuer)
Common Stock, $0.001 par value per share
 (Title of Class of Securities)
23282W 60 5
 (CUSIP Number)
March 1, 2016
 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   o  Rule 13d-1(b)
   x  Rule 13d-1(c)
   o  Rule 13d-1(d)

_______________
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
      The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Cytokinetics Inc (NASDAQ:CYTK)

Page 1 of 14